non-invasive detection of volatile metabolites in parkinson's disease

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is the second most common neurodegenerative disorder. currently, a diagnostic test for early pd does not exist. the aim to address this problem by developing a non-invasive breath test to differentiate early pd from controls. small molecules contained in breath, which offers precious information about disease presence, will be analysed. data from the breath molecules and gut bacterial changes occurring in pd will be combined. these bacterial changes have been shown to arise years before the development of pd symptoms. thanks to earlier diagnosis, therapies could start in advance and improve clinical outcomes and quality of life.

detection of volatile organic compounds (vocs) within exhaled breath and other biological matrices (such as urine, blood, saliva and skin) offers an attractive new strategy for non-invasive screening, diagnosis and monitoring of diseases. vocs emitted by the body potentially reflect biochemical processes underlying physio-pathological states (smith 2007). non-invasive breath tests are well-accepted by patients, and for this reason they can offer the opportunity of large population screening and early diagnosis that can be crucial for several diseases (belluomo 2021; woodfield 2021). despite breath testing has been proved effective to identify different disease states, among which cancer (woodfield 2022) and infections (kamal 2021), its application to neurodegenerative diseases remains still poorly explored. parkinson's disease (pd) is one of the most common neurodegenerative disorders, with six million people affected worldwide and an incidence rate in rapid increase (armstrong 2020). currently, diagnosis of pd is based primarily on the presence of specific motor symptoms, such as bradykinesia, rigidity and rest tremor, which manifest when the progressive accumulation of lewy body pathology and loss of melanised dopaminergic neurons in the substantia nigra pars compacta is already in a mid-late stage (armstrong 2020). misdiagnosis is common on clinical criteria alone, particularly at early presentation when symptoms overlap with other parkinson-plus syndromes and secondary parkinsonism conditions (rizzo 2016). identification of novel biomarkers could lead to earlier and more accurate diagnoses and consequently remarkably improve patient management and quality of life. it is hypothesised that specific voc signatures differentiate pd patients from healthy controls. the microbiome alterations found in pd could be at the origin of voc decreased or increased production. the study recruitment will comprise patients with pd (50), healthy controls (mainly patient's partners or carers 50), and 20 de-novo not medicated pd patients. different tyoes of samples will be collected (i) breath for volatile organic compound analysis (ii) stool for microbiome characterisation and (iii) blood for microvesicles extraction.

Eligibility criteria:
inclusion criteria \[pd group\]: * (i) patients undergoing neurological examination for confirmed or suspected parkinson's disease * (ii) patients aged ≥18 years and below 90 years of age; * (iii) patients off antibiotic or probiotic therapies for at least the last 4 weeks; * (iv) patients without formal diagnosis of dysbiotic conditions; * (v) patients with capacity. inclusion criteria \[healthy volunteers\]: * (i) healthy volunteers that may be or not partner or carer of a parkinson's patient; * (ii) subject aged ≥18 years and below 90 years of age; * (iii) patients off antibiotic or probiotic therapies for at least the last 4 weeks; * (iv) patients without formal diagnosis of dysbiotic conditions; * (iiv) subject with capacity.

Keywords: volatile organic compounds